Stockholm, 2026-01-08

BrainZell, a leader in next-generation brain therapies, will attend the prestigious J.P. Morgan Healthcare Conference in San Francisco from January 12-16th.

The annual event is the world’s leading life science partnering and investor meeting, bringing together industry leaders, innovative technology creators, and the investment community. The BrainZell team, led by its CEO Petra Szeszula, is looking forward to connecting with current and prospective partners, investors, and collaborators to discuss the future of neuroscience and drug discovery.

Accelerating Brain Therapies with AI and Patient-First Biology

BrainZell will be showcasing its proprietary AI-native, patient-first biology platform, which is designed to accelerate the discovery and development of brain therapies. The platform centers around advanced physiological patient-derived brain organoids and an integrated AI system.

“JPM Health Conference is an essential moment for the pharma & biotech community to connect, exchange ideas, and build the partnerships that move science forward,” said Petra Szeszula.

Our platform, built by top talent from institutions including The Johns Hopkins University, Karolinska Institute, and AstraZeneca, represents a significant leap forward in understanding and treating complex brain conditions. We are excited to share how we aim to accelerate life-changing brain therapies.

The company invites attendees to reach out and set up time to learn more about its innovative approach and collaborative opportunities during the conference.